The kit arrives in a padded envelope and weighs almost nothing.
A swab, a tube, a leaflet, a prepaid return mailer.
You rub the swab along the inside of a cat’s cheek, which the cat resents, drop it in the tube and put the whole thing back in the post.
Four to six weeks later a report appears.
Breed groups, a handful of health markers, a dental section, and a line about how much wildcat is in the mix.
That is the whole of a cat DNA test from the customer’s side, and it costs rather less than one night at an emergency vet.
Why the swab was never the product
Read the business the obvious way and it is a retailer of novelty tests.
Somebody pays once, gets a PDF about their cat, and never buys another one. That is a difficult company to build.
Now read it the other way.
Every kit sold adds a sequenced feline genome to a collection, tagged with a breed, an age, a set of symptoms and an owner willing to answer questions.
That collection is the asset.
A single cat genome tells you almost nothing about disease. Tens of thousands of them, attached to real veterinary outcomes, become a research panel that cannot be bought off a shelf.
What the kit actually reads
The cheek swab collects loose cells, and the laboratory pulls DNA out of them.
The panel looks for specific variants rather than reading everything, which is why a basic result costs about a hundred dollars and a full genome costs three times that.
The health list is short and serious.
It covers 38 or more markers, including the mutations behind hypertrophic cardiomyopathy, polycystic kidney disease and progressive retinal atrophy.
The breed part is the fun bit and the weakest bit.
Most domestic cats are not purebred anything, so the report hands back breed group percentages rather than a pedigree, which is closer to a weather forecast than a birth certificate.
What the record actually says
The founder went on a television investment show asking 250,000 dollars for 5 percent of the company.
One investor later said it was such a crazy pitch that he bought it anyway.
She left with 250,000 dollars for ten, split between two investors at 125,000 each, structured as 8.3 percent equity and 1.7 percent advisory.
At that point the business was tiny.
Roughly 2,500 kits sold in ten months, a little over 200,000 dollars in revenue, and a kit priced at 95 dollars.
Then it moved fast.
Revenue reached about 3.5 million dollars over the following eighteen months, and in June 2022 an animal health company completed the acquisition on terms it did not disclose.
Its chief executive said the addition would inform the company’s future pipeline in precision animal health, which is corporate language for buying the data.
Where the famous number comes from
You will see 93 million dollars quoted as the sale price. It is worth knowing where that comes from.
The buyer never published a figure.
Its quarterly filing showed 93 million dollars spent on acquisitions in that period, and this was the only deal named in it, so the number is an inference rather than a disclosed price.
Other reporting says over 50 million, which is a wide gap for a headline figure.
One of the investors put it this way. They sold the company at such a crazy price that he had to sign a nondisclosure agreement, which is a hint dressed as a confirmation and is not the same thing.
The pattern is ordinary enough. Long genetic records are what make a population legible, whether the samples come from 2,000 wild whales or from house cats.
Even water gets swabbed now, tested for traces of a fish nobody has seen yet, and the value there is the archive rather than any single sample.
What the price tag actually tracks
Notice which direction the numbers moved.
The kit did not get cheaper as the company got more valuable, and the current lineup runs from about 99 dollars for a dental panel to 299 for a whole genome.
The value moved somewhere else entirely.
It went into the freezer full of samples and the spreadsheet of outcomes attached to them, which is a thing a buyer can use and a customer cannot see.
That is the useful lesson from an odd little exit.
When a consumer product is the collection mechanism for something else, the thing on the shelf and the thing being sold are two different objects.
Your cat, it should be said, does not care.
The report comes back with a breed group percentage and a note about a dental risk, and both of those lines were worth more to the buyer of the company than to the owner of the animal.
The acquisition notice has the wording and the date. The business coverage has where the number came from.
Read the whole thing?
Get the week's signal, not the noise
Our sharpest reporting on energy, climate and nature — free, once a week.
